Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech giant Gilead Sciences (NASDAQ:GILD) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Gilead, and see what CAPS investors are saying about the stock right now.

Gilead facts

 

 

Headquarters (founded)

Foster City, Calif. (1987)

Market Cap

$85.1 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$10.0 billion

Management

Chairman/CEO John Martin

President/COO John Milligan

Return on Equity (average, past 3 years)

36.5%

Cash/Debt

$1.9 billion / $8.0 billion

Competitors

Bristol-Myers Squibb 

GlaxoSmithKline

Pfizer 

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 2,253 members who have rated Gilead believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, TMFTailwind, succinctly summed up the Gilead bull case for our community:

Very profitable company, and I expect [Gilead's] streak of profitability to continue to increase. No significant patent expiration until 2018. With the current success in the HIV market, if the company can find success in a new category via R&D efforts, this could turn out to be a big winner.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.